Samsung Biologics' $1.8 Billion PolyPeptide Bid: What the Deal Signals for Global Peptide Manufacturing Capacity

Key takeaways

• Samsung Biologics announced a CHF 44.31-per-share all-cash tender offer for PolyPeptide Group AG on 20 July 2026, implying an equity value of approximately CHF 1.46 billion (roughly US$1.8 billion).
• The offer price represents a 40% premium to PolyPeptide's undisturbed share price prior to acquisition rumours emerging in April 2026.
• PolyPeptide's board unanimously recommended acceptance; the anchor shareholder has irrevocably committed; the tender is expected to open by end-August 2026, targeting year-end close.
• The acquisition is explicitly framed around GLP-1 peptide API demand and extends a documented consolidation wave among the handful of CDMOs that command validated, GMP-grade solid-phase peptide synthesis (SPPS) capacity.
• For research-procurement professionals, the deal reinforces supply-chain concentration risk in specialist peptide API production — a dynamic that will take years to resolve even as headline capacity expands.

The transaction in brief

On 20 July 2026, Samsung Biologics (KRX: 207940.KS) announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG (SIX: PPGN), a leading global contract development and manufacturing organisation specialising in peptide-based active pharmaceutical ingredients (APIs).

Under the terms of the offer, PolyPeptide shareholders will receive CHF 44.31 in cash for each share, representing an implied equity value of approximately CHF 1.46 billion. The transaction is expected to be completed towards the end of 2026, subject to customary offer conditions including a minimum acceptance threshold of 66⅔%, applicable regulatory approvals, and other conditions.

The offer price represents a 40% premium to PolyPeptide's undisturbed share price of CHF 31.65 — the last closing price on the SIX Swiss Exchange on 10 April 2026, the last trading day prior to market rumours regarding a potential acquisition.

After a comprehensive strategic review, PolyPeptide's independent board of directors unanimously recommended that shareholders accept Samsung Biologics' tender offer. The anchor holder, Draupnir, which holds 55.65% of the company, has irrevocably committed against a two-thirds minimum acceptance condition.

Who is PolyPeptide, and why does it matter?

PolyPeptide stands as one of the industry's top peptide CDMOs, distinguished by its advanced technology platform and proven track record, with more than 70 years of API manufacturing heritage and over 1,000 therapeutic peptides produced to date.

The company, which employs roughly 1,400 people, reported revenue of €389 million in 2025 — up 16% over the previous year — and had previously indicated an expected revenue increase of 20% to 25% for 2026. That forward guidance was borne out: strong H1 2026 results showed 41.6% revenue growth and a 20.7% EBITDA margin, with 68% of that revenue now derived from the metabolic therapeutics segment that includes GLP-1 drugs.

PolyPeptide operates a multi-site manufacturing network spanning Switzerland, France, Belgium, Sweden, and the United States. The company's newest large-scale SPPS capacity in Braine-l'Alleud, Belgium — a €100 million facility representing the largest single investment in its 70-year history — commenced production in late 2024, and further expansion projects in France and Sweden are under way.

Samsung's strategic rationale

With this transaction, Samsung Biologics will expand its capabilities beyond antibodies and antibody-drug conjugates (ADCs) to include peptide therapeutics, one of the fastest-growing segments of the biopharmaceutical industry. The deal brings together Samsung Biologics' global manufacturing scale with PolyPeptide's specialised peptide expertise to create a differentiated, end-to-end multi-modality CDMO platform.

John Rim, Chairman of the Board and CEO of Samsung Biologics, described the acquisition as reinforcing the company's long-term growth strategy "by not only broadening our service portfolio with modality expansion into peptides including GLP-1, but by also boosting our geographic reach and proximity further within the U.S., Europe, and India."

The acquisition will allow Samsung Biologics to leverage PolyPeptide Group's peptide-based capabilities and expand its current CDMO offerings beyond antibodies and ADCs, addressing growing demand for peptide-based therapeutics, particularly in obesity and diabetes, including GLP-1 therapies.

The timing is deliberate. Described by one industry tracker as "Korea's largest-ever biopharma deal and a direct bet on the scarcest input in the GLP-1 boom — peptide API capacity, which cannot be built greenfield on a short timeline," the deal underscores how tight obesity-drug supply chains have become.

The wider consolidation wave

The Samsung–PolyPeptide deal is the most prominent transaction in a period of rapid consolidation among specialist peptide CDMOs, all competing to secure validated GMP-SPPS capacity in a market where demand has consistently outstripped projections.

The current consolidation wave — Samsung, Bachem, CordenPharma, Lonza, and Thermo Fisher all expanding — is increasing total capacity but reducing the number of independent decision-makers managing that capacity.

Bachem, PolyPeptide's closest listed peer, has been executing an ambitious multi-site expansion of its own. Bachem announced major investment across its site network, with new funding to improve production facilities at its Bubendorf, Vista, and St Helens sites, along with a new site in Sisseln, in direct response to growing demand for peptide and oligonucleotide therapeutics — citing expectations for the global obesity-drug market to increase by more than 15-fold by 2030. Commercial production ramp-up at Building K in Bubendorf is under way in 2026, while Bachem has also acquired property adjacent to its Vista, California facility to add upstream and downstream capacity.

CordenPharma, for its part, launched a greenfield peptide manufacturing plant in Basel, Switzerland, in March 2025, the first stage of a three-year, $1.08 billion peptide programme targeting increased GLP-1 production capacity in both the US and Europe.

Capital expenditure commitments by the top ten North American peptide CDMOs cumulatively reached approximately $4.2 billion through Q1 2026 against 2024–2026 project timelines.

Capacity concentration: a supply-chain risk for procurement teams

Notwithstanding the scale of these investments, the structural tension between expanding capacity and increasing concentration warrants scrutiny. Approximately 36% of peptide manufacturers were operating at utilisation rates above 80% through 2025, and the top five peptide CDMO providers collectively controlled approximately 56% of global peptide manufacturing capacity.

When a small number of large CDMO operators control the majority of validated GMP-SPPS capacity for drugs that millions of patients depend on, a quality failure, a regulatory enforcement action, or an operational disruption at any one of them has fewer independent backups to absorb the impact.

The net effect on supply-chain resilience depends on whether expansion outpaces concentration — an assessment that will take years to make.

For research-procurement professionals sourcing peptide reference standards, research-grade APIs, or raw materials, the practical implications are threefold. First, the absorption of a major independent CDMO into a large Korean conglomerate changes the competitive dynamics for smaller, non-GLP-1 peptide programmes that previously benefited from PolyPeptide's independent client focus. Second, while the GLP-1 shortage that ran from 2022 through early 2025 was formally resolved, supply remains structurally tight and demand continues to grow as more patients start treatment — meaning additional validated peptide API capacity ultimately reduces the risk of future shortages. Third, pharmaceutical sponsors have become acutely aware that excessive concentration of peptide API supply in Asia-Pacific has created unacceptable supply-chain risk, and Western governments have actively incentivised domestic capacity — a dynamic the Samsung deal complicates, given its Korean ownership of a primarily European manufacturing base.

What comes next

The transaction is expected to close towards the end of 2026, subject to customary conditions, with Samsung planning to launch the formal tender offer by the end of August 2026 with publication of the offer prospectus.

In the short term, PolyPeptide will continue operating its existing contracts with current pharmaceutical clients, and the deal's integration will take time. Over the medium term, Samsung's financial resources could accelerate SPPS capacity expansion projects already under way in Belgium, France, and Sweden.

The global peptide CDMO market is projected to expand at roughly 10% annual growth through 2034. Whether that trajectory is sustained depends partly on whether GLP-1 injectable demand holds as oral small-molecule GLP-1 receptor agonists — such as the recently FDA-approved orforglipron (Foundayo) — erode the injectable share of the anti-obesity market over the medium term.

For now, the Samsung–PolyPeptide deal stands as the clearest single signal that large-scale, GMP-validated peptide synthesis capacity is regarded by the world's major pharmaceutical manufacturers as a genuinely scarce and strategically important resource.